A Phase 2 interventional study of deucravacitinib in Epidermolysis Bullosa Simplex, Ichthyosis and Genodermatosis, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 2 sites in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Centre Hospitalier Universitaire de Nice · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to learn about deucravacitinib treatment in adults with inflammatory epidermal genodermatoses . The main question it aims to answer are: describe efficacity and safety of this treatment.
Participants will take treatments and have to use bullets during the study period.
The patient will have 8 visits After Confirmation of inclusion criteria and no exclusion criteria, the study will be explain to the patient after signing the inform consent and be included in the study Treatment Period (Period 1); challenge period This period will be the first treatment period that will occur from 16 weeks. During this period the patient will see the doctor at the hospital, he will perform the study procedures The second period : dechallenge (period 2): All patients stop their treatment for 12 weeks.
The second treatment period - rechallenge (period 3) the patient will take the treatment for a second 16 weeks period At week 44 - End of study
At each visit:
The investigator at each visit compliance to the treatment and adverse events, Measure vital signs and perform clinical examination.
The patient will assess the different questionnaires, for the study and have blood sample
20 studies on the registry are indexed under Epidermolysis Bullosa Simplex; 5 are open to participants now.
This study's enrollment of 8 is below the median of 19 across 17 interventional studies indexed under Epidermolysis Bullosa Simplex.
Browse Epidermolysis Bullosa Simplex studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 723 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject has at least a mean daily number of 4 new blisters (EBS-sev) OR an ISS > 50/128.
Exclusion Criteria:
challenge-dechallenge -rechallenge design
Drug: deucravacitinib
treatment by deucravacitinib in two phases of challenge
efficacy of deucravacitinib
number of new blister conting every day
Time frame: week 44
Safety of deucravacitinib treatment
record of adverse events
Time frame: week 44
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deucravacitinib
Epidermolysis Bullosa Simplex →
Centre Hospitalier Universitaire de Nice →